nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
![Nextcure logo](https://files.capedge.com/S-1/0001047469-19-002203/g79071.jpg)
Company profile
Ticker
NXTC
Exchange
Website
CEO
Michael Richman
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
475231247
NXTC stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
18 Jun 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
2 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
21 Mar 24
8-K
NextCure Provides Year-End Clinical Pipeline Updates
14 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 18.36 mm | 18.36 mm | 18.36 mm | 18.36 mm | 18.36 mm | 18.36 mm |
Cash burn (monthly) | (no burn) | 967.92 k | 6.10 mm | 5.74 mm | 4.20 mm | 4.23 mm |
Cash used (since last report) | n/a | 2.60 mm | 16.39 mm | 15.41 mm | 11.28 mm | 11.37 mm |
Cash remaining | n/a | 15.76 mm | 1.97 mm | 2.95 mm | 7.07 mm | 6.99 mm |
Runway (months of cash) | n/a | 16.3 | 0.3 | 0.5 | 1.7 | 1.7 |
Institutional ownership, Q4 2023
3.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 41 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 9.14 mm |
Total shares | 838.44 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Canaan X | 838.44 k | $9.14 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Mar 24 | Steven P. Cobourn | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.23 | 93,900 | 209.40 k | 93,900 |
29 Mar 24 | Sourav Kundu | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.23 | 52,900 | 117.97 k | 52,900 |
29 Mar 24 | Sol Langermann | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.23 | 93,900 | 209.40 k | 93,900 |
29 Mar 24 | Timothy Mayer | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.23 | 93,900 | 209.40 k | 93,900 |
29 Mar 24 | Han Myint | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.23 | 93,900 | 209.40 k | 93,900 |
News
HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $8 Price Target
3 Jun 24
HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $8 Price Target
31 May 24
NextCure To Present Phase 1b Data On NC410 And Pembrolizumab Combination at ASCO 2024 June 1, 2024
30 May 24
HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $8 Price Target
3 May 24
Needham Reiterates Buy on NextCure, Maintains $4 Price Target
3 May 24
Press releases
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
30 May 24
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
24 Apr 24
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
8 Apr 24
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
4 Apr 24